Peoples Financial Services CORP. Sells 1,555 Shares of Pfizer Inc. (NYSE:PFE)

Peoples Financial Services CORP. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,037 shares of the biopharmaceutical company’s stock after selling 1,555 shares during the quarter. Pfizer makes up approximately 1.5% of Peoples Financial Services CORP.’s investment portfolio, making the stock its 15th biggest holding. Peoples Financial Services CORP.’s holdings in Pfizer were worth $3,339,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of PFE. 25 LLC acquired a new stake in Pfizer in the first quarter valued at approximately $25,000. Worth Asset Management LLC purchased a new position in Pfizer during the 1st quarter worth $29,000. Freedom Wealth Alliance LLC acquired a new position in Pfizer during the 4th quarter valued at about $35,000. Macroview Investment Management LLC raised its stake in Pfizer by 70.0% in the first quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 396 shares during the last quarter. Finally, GeoWealth Management LLC purchased a new stake in shares of Pfizer during the first quarter worth about $49,000. Institutional investors own 68.05% of the company’s stock.

Pfizer Trading Down 0.2 %

PFE opened at $34.07 on Monday. The business has a fifty day simple moving average of $35.80 and a 200-day simple moving average of $37.96. Pfizer Inc. has a 52 week low of $33.54 and a 52 week high of $54.93. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. The firm has a market cap of $192.36 billion, a P/E ratio of 9.06, a P/E/G ratio of 1.14 and a beta of 0.59.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.10. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $13.36 billion. During the same quarter in the prior year, the business earned $2.04 EPS. Pfizer’s revenue was down 54.1% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 3.33 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 4.81%. The ex-dividend date of this dividend was Thursday, July 27th. Pfizer’s dividend payout ratio is presently 43.62%.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Truist Financial reissued a “buy” rating and set a $62.00 target price on shares of Pfizer in a research report on Wednesday, September 13th. Morgan Stanley reduced their target price on Pfizer from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price objective on shares of Pfizer in a report on Tuesday, September 5th. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $45.00 to $41.00 and set a “neutral” rating for the company in a research report on Monday, July 17th. Finally, HSBC assumed coverage on shares of Pfizer in a report on Friday, July 14th. They issued a “buy” rating and a $50.00 price objective on the stock. Twelve research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $46.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.